<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608555</url>
  </required_header>
  <id_info>
    <org_study_id>SP2</org_study_id>
    <secondary_id>2011-001821-26</secondary_id>
    <nct_id>NCT01608555</nct_id>
  </id_info>
  <brief_title>Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis</brief_title>
  <official_title>Tobramycin 300 mg o.d. Aerosol in in Adult Patients With Cystic Fibrosis: Pilot Study on Antimicrobial Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will include 10 adult patients with cystic fibrosis. The aim of the study is to
      evaluate whether Tobramycin 300 mg aerosol once-a-day for 28 days can reduce the bacterial
      load in the airways. Secondary end-point is the evaluation of variation in bacterial
      susceptibility during and at the end of study period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ten adult patients with cystic fibrosis will be enrolled in a stable phase and will received
      prophylaxis with aerosol of Tobramycin 300 mg once a day for 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of bacterial load decrease</measure>
    <time_frame>day 7-9 vs day 1, day 14-16 vs day 7-9, day 28-30 vs day 14-26</time_frame>
    <description>Bacterial load in sputum will be evaluated during and at the end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of inflammatory serum biomarker</measure>
    <time_frame>day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16</time_frame>
    <description>Serum levels of biomarker (PCT) will be evaluated during and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum biomarker</measure>
    <time_frame>day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16</time_frame>
    <description>Evaluation of C-reactive protein levels during and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of serum biomarker</measure>
    <time_frame>day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16</time_frame>
    <description>Evaluation of KL6 levels during and at the end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluation of serum biomarker</measure>
    <time_frame>day7-9 vs day 1, Day 14-16 vs day 7-9, Day 28-30 vs 14-16</time_frame>
    <description>Evaluation of interleukin 6 during and at the end of treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>inhaled tobramycin once-a-day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult patients, with cystic fibrosis, requiring inhaled tobramycin prophylaxis. Patient will be treated with a single dose of 300 mg tobramycin od for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin</intervention_name>
    <description>inhaled tobramycin 300 mg single dose OD for 28 days</description>
    <arm_group_label>inhaled tobramycin once-a-day</arm_group_label>
    <other_name>Bramitob</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients, male and female, age range 18-45 years

          -  Diagnosis of cystic fibrosis

          -  FEV1 &gt;50% predicted.

          -  sputum samples available

          -  Chest x ray negative for pneumonia and tuberculosis

          -  Informed consent

        Exclusion Criteria:

          -  Allergy to tobramycin

          -  Use of systemic steroids in the previous 2 weeks

          -  Pregnancy or breast feeding

          -  Treatment with other experimental drug in the previous 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanna Pizzamiglio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Milan Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Ospedale Maggiore Policlinico via F. Sforza 35</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milan</investigator_affiliation>
    <investigator_full_name>Francesco Blasi</investigator_full_name>
    <investigator_title>Professor of respiratory medicine</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>bacterial load</keyword>
  <keyword>inhaled tobramycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

